Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 ...

Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has ...

Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent (dupilumab), for the treatment of adult patients with bullous pemphigoid (BP ...

Regeneron, Sanofi: FDA Approves Dupixent To Treat Adult Patients With Bullous Pemphigoid June 20, 2025 — 01:41 am EDT Written by RTTNews.com for RTTNews -> ...

Consequently, Sanofi has decided to let go of KT-474, which was being evaluated for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD) in two phase IIb dose-ranging studies.

Sanofi plans to initiate a Phase 1 study of KT-485 next year. It has also decided to exercise its participation election right for the IRAK4 target. As per the agreement, Kymera achieved a $20 ...

Sanofi's Riliprubart Secures U.S. Orphan Drug Status For Solid Organ Transplant Rejection June 25, 2025 — 01:39 am EDT Written by RTTNews.com for RTTNews -> ...

(RTTNews) - French drug major Sanofi S.A. (SNYNF,SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to riliprubart, a monoclonal antibody ...

Adagene Inc. announced that Sanofi will invest up to $25 million and exercise its option for a third SAFEbody discovery program, furthering their strategic partnership. The investment will fund ...

Sanofi SNY announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion recommending the approval of its blood ...

Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational drug, riliprubart, for the treatment of antibody-mediated rejection (AMR) in solid organ transplantation.